β-glycosidase

β-glycosidase-IN-1 is a piperidine derivative, and is an inhibitor of β-glycosidase. It has hypoglycemic activity.

Miglitol (BAY1099) is an alpha-Glucosidase Inhibitor with antihyperglycemic activity.

DNJNAc, also known as 2-Acetamido-1,2-dideoxynojirimycin, is a highly potent and specific inhibitor of β-hexosaminidase (HEX). HEX enzymes catalyze the hydrolysis of terminal non-reducing N-acetyl-β-D-glucosamine (GlcNAc) and N-acetyl-β-D-galactosamine (GalNAc) residues from glycoconjugates such as glycoproteins, gangliosides, and glycosaminoglycans. HEX secreted by chondrocytes into the extracellular space contributes to cartilage matrix degradation, and HEX activity is elevated in the synovial fluid of osteoarthritis patients.

Gcase activator 2 is a β-glucocerebrosidase activator that induces dimerization of GCase at the endoplasmic reticulum (ER) and lysosomal pHs, increases lysosomal substrate metabolism, and has therapeutic potential for the treatment of Parkinson's and Gosheimer's diseases.

Glycosidase-IN-1 is a glycosidase inhibitor synthesized from D-mannose with hypoglycemic activity. It can be used to synthesize some immunosuppressive agents and β-glucosidase inhibitors.

Cyclophellitol is an inhibitor of β-glycosidase, with an IC50 of 0.8 μg/mL.

Cyclo(D-Pro-L-Val) inhibits the activity of β-glucosidase (β-glycosidase) with an IC50 of 75 μg/mL and exhibits either no inhibitory effects or only weak inhibition on other glycosidases.

Glycosidase-IN-2 is a glycosidase inhibitor with hypoglycemic activity.

Resinacein L is an inhibitor of α-glucosidase with an IC50 of 0.635 mM. This compound can slow the digestion and absorption of carbohydrates, thereby reducing postprandial blood glucose levels.

α-Glucosidase-IN-76 (Compound 4r) is an inhibitor of α-glucosidase, with an IC50 of 5.44 μM. It can clear ABTS+ free radicals, with a TEAC value of 0.49. Additionally, α-Glucosidase-IN-76 inhibits the proliferation of T24 bladder cancer cells, with an IC50 of 1.74 μM.

α-Glucosidase-IN-77 (Compound H7) is a non-competitive α-glucosidase inhibitor with an IC50 of 1.25 μM. It reduces blood glucose levels, improves glucose tolerance, regulates gut microbiota, and exhibits hepatoprotective effects in a mouse model of type 2 diabetes.

α-Glucosidase-IN-83 (compound I-1) is a potent inhibitor of α-glucosidase, demonstrating an IC50 of 1.49 μg/mL. This compound effectively reduces blood glucose levels in vivo.

α-Glucosidase-IN-82 (compound 8l) is a potent inhibitor of α-glucosidase, with an IC50 value of 13.66 μM. Its inhibitory activity is 52 times greater than that of Acarbose.

α-Glucosidase-IN-78 (Compound 12m) is a reversible competitive inhibitor of α-glucosidase (α-glucosidase) with an IC50 of 6.0 μM. Due to its blood sugar-lowering properties, α-Glucosidase-IN-78 is applicable in diabetes research.

α-Glucosidase-IN-79 (Compound 4d9) is a non-competitive α-glucosidase inhibitor with an IC50 of 2.11 μM, demonstrating greater inhibitory potency than the existing α-glucosidase inhibitors Acarbose (IC50 of 327.0 μM) and HXH8r (IC50 of 15.32 μM). It exhibits no cytotoxicity on normal human liver cells (LO2) and shows good metabolic stability in rat plasma. α-Glucosidase-IN-79 holds promise for research in type 2 diabetes.

α-Amylase/α-Glucosidase-IN-18 (Compound 9g) is an inhibitor of α-amylase and α-glucosidase, with IC50 values of 49.17 nM and 10.71 nM, respectively. It is suitable for research related to type 2 diabetes.

α-Amylase/α-Glucosidase-IN-17 (Compound 3) is an inhibitor of α-amylase and α-glucosidase, with IC50 values of 14.61 μM and 25.38 μM, respectively. It exhibits some inhibitory activity against A549 cancer cells and possesses both antitumor and antidiabetic properties.

α-Amylase-IN-12 (Compound 5e) is an α-amylase inhibitor with an IC50 of 0.15 mM, functioning through a mixed inhibition mode. It exhibits an IC50 of 9.40 mM against α-glucosidase. This compound enhances glucose uptake in yeast cells and demonstrates significant anti-glycation activity at high concentrations. α-Amylase-IN-12 is applicable for diabetes research.

α-Glucosidase-IN-84 (Compound 7j) is a competitive inhibitor of α-glucosidase, exhibiting an IC50 of 50 μM and a Ki of 32 μM. It shows potential for application in metabolic disease research, particularly in studies related to type 2 diabetes.

α-Glucosidase-IN-80 (Compound 10n) is a potent competitive inhibitor of α-glucosidase, with an IC50 of 48.4 μM. It exhibits favorable pharmacokinetic properties and toxicity profiles, making it suitable for research in diabetes-related conditions.

α-Glucosidase-IN-87 (Compound 11c) is an orally active inhibitor of α-glucosidase with an IC50 of 119.7 μM. It exhibits hypoglycemic properties and is applicable in research on metabolic diseases such as diabetes.

α-Glucosidase-IN-85 (Compound 8D1) functions as an inhibitor of α-Glucosidase, with an IC50 of 5.43 μM. This compound is useful for research related to type 2 diabetes.

α-Glucosidase-IN-86 (Compound A4) is an orally active α-glucosidase inhibitor with an IC50 of 2.72 μM. In mice, it demonstrates high safety and effectively reduces fasting blood glucose levels, improves glucose tolerance, regulates blood lipids, and exhibits antioxidant properties in diabetic models. α-Glucosidase-IN-86 is suitable for diabetes research.

α-Glucosidase-IN-89 (8g) is an inhibitor of α-glucosidase, with an IC50 of 0.5 μM and a Ki of 0.46 μM.